JANSSEN-CILAG yesterday
announced a locally signed
agreement with Sanofi-Aventis
Australia Pty Ltd (Sanofi) to
combine efforts to co-promote
their respective diabetes therapies
Invokana (canagliflozin) and Apidra
(insulin glulisine) in Australia,
effective immediately.
The agreement brought together
Janssen’s oral diabetes treatment
Invokana, with Sanofi’s experience
in assisting people living with
diabetes to manage their condition,
Janssen Australia and New Zealand
md Chris Hourigan said.
Invokana is a sodium glucose cotransporter
2 (SGLT2) inhibitors and
Apidra is a short-acting insulin.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jul 14
THE Australian Commission on Safety and Quality in Health Care has today launched a national Standard to improve the care of people with cognitive disabilities or impairments.
AUSTRALIAN mothers and their babies experienced some positive outcomes during the early years of the pandemic, new research from the Australian Institute of Health and Welfare (AIHW) has discovered.
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.